Pro Forma Cash of $105 Million; Interim Registrational ACR-368 Data in 2H:26

Research evidence excerpt

Pro Forma Cash of $105 Million; Interim Registrational ACR-368 Data in 2H:26

OncoSignature+ patients at 16 weeks. Importantly, serous patients across both Shares Out (mil) 42.8

arms with ≤2 PLOT achieved a 52% (12/23) ORR, 74% (17/24) DCR and 65% (16/24) Form 10Q as of May 8th

CBR at 16 weeks. Serous histology reflects a severe phenotype that accounts for Market Cap. (mil) US$82.2

10-15% of 1st-line and ~50% of 2nd-line+ EC patients with higher mortality. We think Total Assets ($mil) NA

Acrivon is addressing a severe unmet medical need in serous EC patients who Avg Daily Vol (000) 804

Book Value/Share NA currently lack effective targeted treatment options. In the Phase IIb trial, Acrivon is

Net Cash Per Share US$2.45

enrolling Arm 3 of ACR-368 + ULDG and Arm 4 of ACR-368 monotherapy with 90 serous 1Q:26 cash plus April ATM

EC patients each with ≤2 PLOT for potential approval. Acrivon now plans to conduct a Debt to Total Capital 0.0%

prespecified simultaneous interim analysis of Arms 3 and 4 in 2H:26. Based on interim Div Yield 0.00%

data, Acrivon plans to complete enrollment of Arm 3 or Arm 4 by 4Q:26 with data likely Fiscal Year End Dec

in 2027. Acrivon is planning a confirmatory Phase III trial of ACR-368 in combination

with anti-PD-1 therapy Price Performance - 1 Year

USD

• More ACR-2316 Data this Year. ACR-2316 is a dual WEE1 and PKMYT1 inhibitor. 3.5

Acrivon treated 33 patients escalating up to 160mg ACR-2316 in a 3-day on/4-day off 3

regimen (N=4) and up to 240mg ACR-2316 in a 2-day on/5-day off regimen (N=10).

ACR-2316 was well tolerated with mostly transient neutropenia and no GI tox. At doses 2.5

of 120mg+ ACR-2316, tumor shrinkage was observed in 45% (9/20) patients. PRs were 2

observed in EC, SCLC and sqNSCLC. Acrivon is now exploring a bi-weekly dosing